The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: An economic evaluation of the ZUMA-7 trial

Large B-cell lymphoma (LBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). In 2016, around 28,000 new cases were diagnosed in the United States (US).(1) Overall, 10-15% have primary refractory LBCL, and an additional 20 - 25% of patients with LBCL will ultimately relapse from first-line therapy after an initial response.(2) Prior to chimeric antigen receptor (CAR) T-cell therapies, potentially curative treatments for patients with second-line LBCL who would receive salvage immunochemotherapy followed by high-dose chemotherapy included autologous stem cell transplant (auto-SCT), and then allogeneic-SCT (allo-SCT) for those who fail auto-SCT.